Highlights d Macrophages are immunosuppressive because of upregulated PD-L1 and IDO after ADCP d AIM2 is recruited to phagosomes and activated by tumor DNA in ADCP macrophages d AIM2 cleaves cGAS and upregulates PD-L1 and IDO by caspase-1/IL-1b d Synergistic effects between therapeutic antibodies and ICIs are macrophage dependent SUMMARY Antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) critically contribute to the efficacy of anti-tumor therapeutic antibodies. We report here an unexpected finding that macrophages after ADCP inhibit NK cell-mediated ADCC and T cell-mediated cytotoxicity in breast cancers and lymphomas. Mechanistically, AIM2 is recruited to the phagosomes by FcgR signaling following ADCP and activated by sensing the phagocytosed tumor DNAs through the disrupted phagosomal membrane, which subsequently upregulates PD-L1 and IDO and causes immunosuppression. Combined treatment with anti-HER2 antibody and inhibitors of PD-L1 and IDO enhances antitumor immunity and anti-HER2 therapeutic efficacy in mouse models. Furthermore, neoadjuvant trastuzumab therapy significantly upregulates PD-L1 and IDO in the tumor-associated macrophages (TAMs) of HER2 + breast cancer patients, correlating with poor trastuzumab response. Collectively, our findings unveil a deleterious role of ADCP macrophages in cancer immunosuppression and suggest that therapeutic antibody plus immune checkpoint blockade may provide synergistic effects in cancer treatment.
In Brief
Therapeutic antibody-based cancer treatment leads to ADCP-induced, AIM2mediated immunosuppression by macrophages that can be overcome with concomitant immune checkpoint blockade.
INTRODUCTION
Monoclonal antibody is a major category of therapeutic agents for various malignancies. For instance, trastuzumab (Herceptin), a humanized anti-HER2 monoclonal antibody for breast and gastric cancers, and rituximab (Rituxan), a chimeric anti-CD20 monoclonal antibody for lymphoma and leukemia, are widely used in the clinic. Immune responses mediated by Fc gamma receptors (FcgRs) on the innate immune cells are critically involved and determine the efficacy of therapeutic antibodies (Clynes et al., 2000) . Interaction between antibody Fc fragment and FcgRs eliminates antibody-bound tumor cells via antibody-dependent cellular cytotoxicity (ADCC) mainly by natural killer (NK) cells, or via antibody-dependent cellular phagocytosis (ADCP) mainly by macrophages (Clynes et al., 2000; Michaud et al., 2014) . ADCC has been studied extensively and is critical for the tumoricidal effects of therapeutic antibodies, in which immune cells bind to cancer cells via antibodies and lyse them by releasing perforin and granzymes (Zhu et al., 2015) . In contrast, much less is known about the overall effect of ADCP on tumors and their microenvironment. It was suggested that ADCP is tumoricidal as macrophages phagocytose antibody-bound tumor cells (Chao et al., 2010) . However, phagocytosis of apoptotic cells by macrophages in damaged tissue can induce immunosuppression, leading to immune tolerance (Perruche et al., 2008) .
NK cells and tumor-specific T cells are two major immune cell types responsible for anti-tumor immunity, but their activities can be inhibited by immune checkpoints, such as programmed death-1 (PD-1) and indoleamine 2,3-dioxygenase (IDO) (Curiel et al., 2003; Munn and Mellor, 2016) . Interaction between PD-1 expressed mainly on activated T and NK cells (Mellman et al., 2011; Morvan and Lanier, 2016) and its ligands, PD-L1 on tumor and myeloid cells and PD-L2 mainly on dendritic cells (DCs) (Zou et al., 2016) , suppresses the tumoricidal functions of effector immune cells. Additionally, IDO converts tryptophan to a number of immunosuppressive molecules and subsequently inhibits the functions of both T and NK cells (Prendergast et al., 2014) . Recently, immune checkpoint inhibitors (ICIs) have demonstrated their therapeutic effects in cancer (Sharma and Allison, 2015) . Activated oncogenic signaling, such as MYC (Casey et al., 2016) and PI3K (George et al., 2017) , can upregulate the expression of immune checkpoints in cancer cells. Nevertheless, mechanisms governing PD-L1 and IDO expression in macrophages, a major source of immune checkpoint molecules in tumor microenvironment (Noy and Pollard, 2014) , are not clear yet. Here, we investigated whether and how therapeutic antibody-mediated ADCP influence anti-tumor immunity and therapeutic effects with the goal of finding new strategies to improve the clinical efficacy.
RESULTS

ADCP Converts Macrophages into an Immunosuppressive Phenotype
To investigate whether trastuzumab can induce ADCP of tumor cells in primary human macrophages, we labeled HER2 + breast cancer cell lines (SKBR3 and with CellTracker Deep Red (CTDR) and co-cultured them with 5-chloromethylfluorescein diacetate (CMFDA)-labeled monocyte-derived macrophages for 24 hr in the presence or absence of trastuzumab or a control isotype immunoglobulin G (IgG) . We found that trastuzumab, but not IgG control, dose-dependently increased the proportion of macrophages positive for both dyes ( Figure S1A ). Confocal microscopy also demonstrated that trastuzumab significantly increased the fluorescent puncta of tumor debris within macrophages ( Figure 1A) . Furthermore, the puncta in the macrophages from trastuzumab group were markedly larger (0.7-3.2 mm in diameter) than those in the IgG or untreated group ($0.7 mm), indicating trastuzumab-induced phagocytosis of HER2 + cancer cells by human macrophages (Figures 1A and S1B ). To determine which FcgR mediates trastuzumab-dependent tumor phagocytosis by human macrophages, we added neutralizing antibodies against three activating FcgRs, including CD64, CD32a, and CD16. Neutralizing CD16 or CD32a significantly inhibited trastuzumab-induced ADCP. CD64 blockade marginally reduced the double-positive cell proportion. Moreover, ADCP was almost completely abolished in macrophages devoid of all three activating FcgRs (Figure S1C) . Together, these results suggest FcgRs, especially CD16 and CD32a, mediate trastuzumab-dependent tumor phagocytosis by human macrophages.
To address whether ADCP in macrophages influence ADCC in NK cells, macrophages were pre-incubated with HER2 + breast cancer cells in the presence or absence of trastuzumab for 24 hr and then co-cultured with autologous NK cells. The ADCC activities of these NK cells were evaluated by co-culturing them with HER2 + SKBR3 and BT-474 breast cancer cells with or without trastuzumab (Figure 1B) . As expected, treatment with trastuzumab triggered ADCC by markedly increasing the perforin and granzyme B production and tumoricidal effects of NK cells ( Figure 1C) . Importantly, we observed that macrophages pre-incubated with HER2 + tumor cells in the presence of trastuzumab (ADCP macrophages), but not untreated macrophages (MF) or tumor co-cultured macrophages without trastuzumab (tumor-co-cultured [TC] macrophages), significantly inhibited NK cell proliferation stimulated by interleukin-2 (IL-2) and IL-15 (Figures S1D and S1E) and suppressed NK cell-mediated ADCC when co-cultured with HER2 + tumor cells in the presence of trastuzumab ( Figures 1C and S1E) . In contrast, pre-incubation of macrophages with BT-474 cells whose HER2 was genetically eliminated by CRISPR-Cas9 even in the presence of trastuzumab did not have any suppressive effect on NK cell-mediated ADCC against HER2 + tumor cells ( Figure S1E ), indicating the suppression on ADCC by macrophages is dependent on ADCP. To further confirm this, we inhibited phagocytosis by latrunculin A, a cytochalasins inhibiting actin polymerization, or blocked the three FcgRs with a neutralizing antibody cocktail ( Figure S1F ). Unsurprisingly, inhibition of phagocytosis reversed the suppression on NK cell proliferation and ADCC against tumor cells by macrophages ( Figures 1D and S1G ).
Since adaptive immunity via both CD8 + and CD4 + T cells is also essential for the therapeutic effects of antibody (Mortenson et al., 2013; Park et al., 2010) , we next investigated whether ADCP macrophages can also influence the functions of tumorspecific T cells that were generated by incubating CD8 + or CD4 + T cells with autologous DCs pulsed with tumor lysates as we previously reported (Su et al., 2017) . We observed that ADCP macrophages dramatically inhibited the proliferation, production of perforin and granzyme B, and tumoricidal effects of tumor-specific CD8 + T cells and interferon (IFN)-g level of tumor-specific CD4 + T cells ( Figure S1H ), which were abolished when ADCP was inhibited ( Figure S1I ). 
Experimental schematic: human macrophages were cultured alone (MF) or co-cultured with human HER2 + breast cancer cells or CD20 + lymphoma cells in the absence (tumor co-cultured macrophages, TC-MF) or presence of trastuzumab or rituximab (ADCP-MF) for 24 hr. The macrophages were then co-cultured with autologous NK cells for 4 days, and the NK cells were evaluated for their ADCC capacity against tumor cells. (C) NK cells co-cultured with indicated macrophages were labeled by CTDR and co-incubated with HER2 + SKBR3 cells labeled by CMFDA with or without trastuzumab for 18 hr. The NK cells were stained for intracellular granzyme B or perforin. Dead tumor cells were assessed by propidium iodide (PI) uptake. Live NK (CMFDA -PI -) cells were gated for anti-CD107a staining. (D) Macrophages were co-cultured with SKBR3 cells in the presence of trastuzumab (red) or with Raji cells in the presence of rituximab (green). Latrunculin A or a FcgR-neutralizing antibody cocktail was added to block ADCP. After 24 hr, the macrophages were co-cultured with autologous NK cells. The proliferation, perforin, granzyme B, and ADCC capacity of co-cultured NK cells were subsequently evaluated by flow cytometry. Representative plots are shown in Figure S1G . (E) Representative immunohistochemistry (IHC) staining of CD68, CD56, and CD8 in the serial sections of resected breast cancer samples from sensitive and resistant patients after neoadjuvant trastuzumab therapy. Scale bar, 200 mm. (F) Quantitation of (E). Sensitive group, n = 154, Resistant group, n = 50. (G) Experimental schematic: mouse breast cancer E0771 cells were transduced with human ErbB2 (huErbB2) expression vectors and injected into ErbB2 + ;Csf1 op/op mice. Mice were treated with 4D5 (mouse-anti-human HER2 antibody) when the syngeneic grafts were palpable. (H) Syngeneic grafts of mice injected with wild-type E0771 cells (E0771/WT) or E0771 cells transduced with human ErbB2 (E0771/ErbB2 + ). IHC staining confirmed human HER2 expression in the residual tumor grafts after treatment. Scale bar, 50 mm. (I) Tumor growth curves. (J) The representative pictures of (K) . Asterisks indicate the area with higher magnification in the upper-right corner. Scale bar, 50 mm. (K) Quantitation of CD49b + NK cells, CD8 + cells, and TUNEL + tumor cells in the harvested grafts. See also Figure S1 . Numerical values denote mean ± SEM (n = 5: C and D; n = 8: I and K). * and # p < 0.05; ** and ## p < 0.01; *** and ### p < 0.001 by Student's t test (versus the 2 nd group in C and D or as the line indicated in F, I, and K).
To evaluate whether the suppression of anti-tumor immunity by ADCP represents a general phenomenon of therapeutic antibodies, we co-cultured primary human macrophages with CD20 + Raji lymphoma cells in the presence of rituximab, where we could observe a whole Raji cell engulfed in ADCP macrophages ( Figure S1J ). Furthermore, the percentages of tumor cell eradicated was higher in rituximab group than trastuzumab group (Figures S1K and S1L), suggesting that macrophages are more efficient to phagocyte lymphoma cells than breast cancer cells. Consistent with the findings in breast cancer, macrophages co-cultured with Raji cells in the presence of rituximab, but not untreated macrophages or those co-cultured without rituximab, significantly inhibited the proliferation and rituximab-dependent lymphoma cell cytotoxicity of NK cells ( Figure S1M ). Likewise, such suppressive effects were abrogated by phagocytosis inhibition ( Figure 1D ). Taken together, our data suggested that macrophages undergone ADCP are immunosuppressive and inhibit anti-tumor functions of NK cells and tumor-specific T cells.
Macrophages Compromise the Anti-tumor Effects of Therapeutic Antibodies via Immunosuppression
Neoadjuvant (preoperative) therapy is an ideal clinical model to evaluate the therapeutic response as tumor shrinkage and tumor biology can be monitored during treatment. To evaluate the role of macrophages in trastuzumab response of patients, we examined the density of CD68 + macrophages, CD56 + NK cells, and CD8 + T cells in the primary tumors resected from 204 HER2 + breast cancer patients after neoadjuvant trastuzumab therapy. We observed that macrophages were scarcely found in the residual tumor tissues of 154 patients who responded to therapy (responders) but were abundant in the tumors from 50 patients who did not respond (non-responders). In contrast, infiltration of NK and CD8 + T cells were significantly higher in the residual tumor tissues of responders than those from non-responders (Figures 1E and 1F) . Moreover, the number of tumor-associated macrophages (TAMs) after neoadjuvant trastuzumab therapy was negatively correlated with those of NK cells and CD8 + T cells ( Figure S1N ), suggesting that the presence of macrophages is associated with immunosuppression and poor response in the breast cancer patients receiving trastuzumab.
Trastuzumab is developed from its parental drug 4D5, a mouse anti-human HER2 antibody. To evaluate the therapeutic effects of antibody in vivo, we ectopically expressed human ErbB2 in E0771 cells, a C57/BL6 mouse breast cancer cell line, and injected these cells into immunocompetent pWAP-human ErbB2 (ErbB2 + ) mice, a huErbB2 knockin C57/BL6 mouse model with human HER2 immune tolerance. Treatment with 4D5 was initiated when the tumor grafts became palpable ( Figure 1G ) and human HER2 expression in tumor grafts was confirmed by immunostaining ( Figure 1H ). To further investigate the role of macrophages in this model, we crossed huErbB2 knockin mice with Csf1-deficient mice (ErbB2 + ;Csf1 op/op , Figure 1G ), in which macrophages were ablated due to the loss of the major lineage regulator (Noy and Pollard, 2014) . No significant difference in tumor size was observed between the ErbB2 + mice and ErbB2 + ;Csf1 op/op ones treated with IgG control antibody ( Figure 1I ), consistent with previous reports that depletion of macrophages has little effect on primary breast cancer growth (Lin et al., 2001) . However, treatment with 4D5 was significantly more effective to inhibit tumor growth in the ErbB2 + ;Csf1 op/op mice than in the ErbB2 + mice ( Figure 1I ). Additionally, immunofluorescent staining demonstrated that Csf1 knockout resulted in remarkably increased infiltration of CD49b + NK and CD8 + T cells in the tumors and enhanced apoptosis of tumor cells denoted as cytokeratin + TUNEL + cells in the tumor grafts of 4D5-treated mice, but not in those treated with IgG ( Figures 1J  and 1K ), suggesting that TAMs reduce the therapeutic effects of antibody by immunosuppression.
PD-L1 and IDO Mediate the Immunosuppressive Effects of ADCP Macrophages
To identify the mechanism responsible for immunosuppressive effects of ADCP macrophages, we compared the mRNA expression profiles of the macrophages with or without trastuzumabdependent tumor phagocytosis ( Figure 2A ). We performed an unbiased gene expression analysis for the inhibitory immune checkpoint molecules. PD-L1 and IDO emerged as the most upregulated ones in ADCP macrophages than untreated macrophages, which were further confirmed by qRT-PCR ( Figure S2A ). Consistently, the protein levels of PD-L1 and IDO were markedly higher in ADCP macrophages (Figures 2B and 2C) , which was abrogated by FcgR neutralization ( Figure S2B ). Similarly, PD-L1 and IDO levels also significantly increased in the macrophages after rituximab-dependent phagocytosis of Raji cells ( Figure S2C ).
To investigate whether PD-L1 and IDO mediate the immunosuppressive effects of ADCP macrophages, we added anti-PD-L1 antibody or IDO inhibitor (1-MT) to the co-cultures of macrophages and NK cells and found that either PD-L1 neutralization or IDO inhibition significantly alleviated the suppressive effects of ADCP macrophages on the proliferation and ADCC of NK cells ( Figure 2D ). Notably, the suppressive effects of ADCP macrophages on NK cells were completely reversed when both anti-PD-L1 antibody and IDO inhibitor were added ( Figure 2D ). Consistently, ADCP-mediated suppression on the (C) IL-1b levels in human macrophages that were co-cultured with or Raji (green) cells with trastuzumab or rituximab, respectively. (D) Representative cleaved IL-1b antibody staining images of human macrophages that were cultured alone or co-cultured with BT-474 cells without or with trastuzumab. Scale bar, 5 mm.
(legend continued on next page) proliferation and tumoricidal effects of tumor-specific CD8 + T cells was also reversed by PD-L1 and IDO blockade (Figure S2D) . Moreover, we also observed that the immunosuppressive effects of macrophages after rituximab-dependent lymphoma phagocytosis were abrogated by antagonizing both PD-L1 and IDO ( Figure S2E ). Thus, our findings suggest that upregulation of PD-L1 and IDO underlies the immunosuppressive effects of ADCP macrophages.
IL-1b Upregulates PD-L1 and IDO in ADCP Macrophages
We observed that PD-L1 and IDO were overexpressed not only in the ADCP macrophages, but also in the adjacent macrophages without ADCP ( Figures 2C and 3A ), suggesting their upregulation may be mediated by autocrinal and paracrinal cytokines. Transcriptomic profiling revealed several cytokines were increased in ADCP macrophages ( Figure S3A ), including IL-1b, CXCL1, CCL8, and IL-6 etc., which was confirmed by qRT-PCR ( Figure S3B ). It has been reported that IFNs play a dominant role in PD-L1 (Zou and Chen, 2008) and IDO (Prendergast et al., 2014) induction in macrophages. While IFN-a, b, and g were slightly increased ( Figure S3C ), neutralizing these cytokines had no appreciable effect on PD-L1 and IDO upregulation in ADCP macrophages ( Figure S3D ). In contrast, IL-1b neutralization significantly suppressed the induction of PD-L1 and IDO in ADCP macrophages ( Figure 3B ). Consistently, bioactive IL-1b was markedly produced by ADCP macrophages (Figures 3C and 3D ). Furthermore, treatment with recombinant human IL-1b significantly upregulated PD-L1 and IDO in macrophages to the levels comparable to ADCP macrophages ( Figure 3B ), while treatment with other cytokines that were increased in the transcriptomic profiling ( Figure S3E ) or neutralizing other TAM-associated secretary mediators ( Figure S3F ) did not have any obvious effect in PD-L1 and IDO induction on macrophages. Similarly, IL-1b secretion was increased in the macrophages after rituximab-dependent lymphoma phagocytosis ( Figure 3C ), while neutralizing IL-1b suppressed PD-L1 and IDO upregulation in these cells ( Figure S3G ). Collectively, our results indicate that bioactive IL-1b released by ADCP macrophages induces their activation to a PD-L1 high-IDO high phenotype.
Since ADCP can also be mediated by DCs (Michaud et al., 2014) , we induced ADCP in monocyte-derived DCs (mo-DC) and found that PD-L1 and IDO were upregulated after ADCP, which could be inhibited by blocking FcgRs or IL-1b ( Figure 3E ). In addition, blockade of PD-L1 and IDO significantly increased perforin expression in NK cells co-cultured with mo-DCs after ADCP ( Figure 3F ). These data indicated that ADCP in DCs may also upregulate PD-L1 and IDO via IL-1b, leading to immunosuppression.
Caspase-1 Activation Induces Bioactive IL-1b in ADCP Macrophages
We next explored mechanisms underlying the production of bioactive IL-1b in ADCP macrophages. Since production of bioactive IL-1b requires caspase-1 activation, we examined caspase-1 activity in the macrophages and found increased levels of the cleaved caspase-1 in ADCP macrophages (Figures 4A, 4B, and S4A) . Western blotting confirmed enhanced conversion of inactivated precursors to cleaved caspase-1 in the supernatant of ADCP macrophages, which is similar to the secretion of bioactive IL-1b ( Figure 4C ). Inhibition of caspase-1 by specific inhibitors Ac-YVAD-CMK and VX765 suppressed the production of bioactive IL-1b ( Figure S4B ) and reversed the upregulation of PD-L1 and IDO in these macrophages ( Figures 4D and 4E ), suggesting that PD-L1 and IDO upregulation is mediated by activated caspase-1/IL-1b in ADCP macrophages.
To investigate whether the factor of caspase-1/IL-1b/PD-L1 and IDO cascade is derived from bound-but-not-phagocytosed dead cells, we induced apoptosis of tumor cells by irradiation or trastuzumab and apoptosis of macrophages by starvation ( Figure S4C ). IL-1b was marginally increased in apoptotic macrophages but not in tumor cells ( Figure S4D ). The level of IL-1b derived from apoptotic macrophages was significantly lower than the one derived from ADCP macrophages ( Figure S4D ). Additionally, FcgR neutralization abolished caspase-1 activation in the ADCP macrophages ( Figure 4F ), indicating the essential contribution of ADCP via FcgR. Furthermore, although monocytes and neutrophils bound, but not phagocytosed target cells when opsonized by antibodies (Beum et al., 2008; Valgardsdottir et al., 2017) , the PD-L1 and IDO in these antibody-opsonized cells were not elevated as in ADCP macrophages ( Figure S4E ). Collectively, our data indicated that the elevation of PD-L1/IDO via caspase-1/IL-1b pathway in macrophages co-cultured with antibody-treated tumor cells is caused by ADCP, but not by bound-but-not-phagocytosed external materials.
AIM2 Senses DNAs of Phagocytosed Tumor Cells and Activates Caspase-1/IL-1b in ADCP Macrophages
Caspase-1 is activated by inflammasomes via the nucleotidebinding domain and leucine-rich repeat-containing (NLR) proteins, including NLRP1, NLRP3, NLRC4, and ALR (AIM2-like receptor) member absent in melanoma 2 (AIM2), a cytosolic DNA sensor for double-stranded DNA (Lamkanfi and Dixit, 2014) . Knockdown of AIM2, but not NLRP1, NLRP3, or NLRC4 ( Figure S4F ), markedly inhibited caspase-1 activation in ADCP macrophages ( Figure S4G ). Western blot confirmed that silencing AIM2 dramatically reduced caspase-1 cleavage and bioactive IL-1b production ( Figure 4G ). Furthermore, co-immunoprecipitation demonstrated increased binding of AIM2 to the (E) MFI (310 3 ) of PD-L1 and IDO in indicated monocyte-derived DCs (mo-DCs) co-cultured with BT-474 cells in the presence of trastuzumab with or without control IgG, IL-1b-neutralizing antibody, or an FcgR-neutralizing antibody cocktail. ***p < 0.001 versus untreated mo-DCs; # p < 0.05, ## p < 0.01, versus control ADCP-DCs by Student's t tests. (F) The expression of perforin in NK cells that were co-cultured with mo-DCs with trastuzumab-dependent BT-474 cell phagocytosis in the presence or absence of PD-L1-neutralizing antibody or/and IDO inhibitor (1-MT). ***p < 0.001 versus NK cells cultured alone; ## p < 0.01, ### p < 0.001 versus NK cells co-cultured with ADCP-DCs by Student's t tests. See also Figure S3 . Numerical values denote mean ± SEM (n = 5: [A] - [C] , [E] , and [F] ). ## p < 0.01; *** and ### p < 0.001 by Student's t test (versus untreated macrophages in A and C). adaptor protein ASC ( Figure 4H ), indicating AIM2 activation and inflammasome formation in ADCP macrophages. AIM2-ASC binding didn't increase in apoptotic macrophages ( Figure S4H ) and little AIM2 was detected in BT-474 and SKBR3 cells (Figure S4I) , indicating AIM2 activation is not derived from dead tumor cells or macrophages. Additionally, confocal analysis revealed co-localization of fluorescence-labeled tumor DNA and AIM2 as well as the formation of AIM2 specks in ADCP macrophages, but not in untreated macrophages or TC macrophages ( Figure 4I ). In addition, transducing macrophages with short hairpin RNA (shRNA) against p65, TBK1, STAT1, and AMPK, respectively, did not result in AIM2 aggregation ( Figure S4J ) or caspase-1 activation ( Figure S4K ), suggesting that none of these pathways plays a key role in AIM2 activation. Thus, our data insinuated that AIM2 is activated by DNAs from phagocytosed tumor cells.
To evaluate the components of phagocytosed DNAs in macrophages after ADCP, we extracted the DNAs from the cytoplasm of untreated or ADCP macrophages and examined the amount of nuclear and mtDNAs (mitochondrial DNAs) using qPCR with a genomic (Polg) or a mitochondrial (Nd1) DNA-specific primer, respectively (Xu et al., 2017) . We observed that both the gDNAs (genomic DNAs) and mtDNAs were significantly increased in the cytoplasm of ADCP macrophages compared to untreated cells, with mtDNAs exhibiting higher abundance ( Figure 4J ). To further distinguish whether the DNAs accumulated in the cytoplasm of ADCP macrophages is endogenous or originated from ingested tumor cells, mouse breast cancer E0771 cells with forced expression of human ERBB2 were co-cultured with human macrophages in the presence of trastuzumab. We observed that mouse DNAs were significantly increased in the ADCP macrophages compared to untreated cells ( Figure 4K ). In contrast, human DNA was not detected in the cytoplasm of ADCP macrophages. Collectively, our data suggested that both tumor gDNAs and mtDNAs, but not the macrophage DNAs, bind to AIM2 and activate inflammasome.
It has been shown that caspase-1 activation may lead to cell death in microbial infection (Galluzzi et al., 2016) . Indeed, cell death was increased in the ADCP macrophages, but caspase-1 activation was also observed in the live cells negative for both PI and annexin V ( Figure S4L ), suggesting that ADCP-induced caspase-1 activation does not always lead to cell death in macrophages. This is in agreement with a previous report that caspase-1 activation is dissociated with cell death in tumor-associated myeloid-derived suppressor cells (Bruchard et al., 2013) .
FcgR Signaling Prioritizes AIM2 Sensing DNA by Recruiting It to Phagosomes
It has been reported that other DNA sensors, such as cyclic GMP-AMP synthase (cGAS)-STING and TLR9, elicit anti-tumor immune response by detecting tumor DNA. However, silencing TLR9 and STING with shRNAs didn't have any appreciable effect on PD-L1 and IDO expression in ADCP macrophages ( Figures 5A, S5A , and S5B). This is in agreement with previous findings that TLR9 predominantly recognizes foreign DNAs with unmethylated CpG motifs (Akira et al., 2006) , while tumor DNAs are highly methylated (You and Jones, 2012) . More interestingly, silencing AIM2 significantly increased cGAS levels and enhanced STING signaling with IRF3 and TBK1 phosphorylation ( Figure 5B ), as well as IFN-b secretion (Figure S5C) in ADCP macrophages, suggesting that AIM2 activation reciprocally antagonizes the cGAS-STING pathway during ADCP. Similarly, a recent report in viral infection demonstrated that inflammasome activation antagonizes the cGAS-STING pathway by caspase-1-mediated cGAS cleavage (Wang et al., 2017) .
Since cGAS can shuttle to lysosome after activation (Gaidt et al., 2017) , we asked whether AIM2 or cGAS may traffic to phagosome in ADCP macrophages. We observed that AIM2, but not cGAS, colocalized with the phagosome marker Rab7 in ADCP macrophages ( Figures 5C and 5D ). We next investigated whether AIM2 shuttling to phagosomes was mediated by FcgR during ADCP. Treatment with inhibitors against spleen tyrosine kinase (SYK), which is required for downstream signal transmission of FcgR (Mó csai et al., 2010) , abrogated the colocalization of AIM2 and Rab7 ( Figure 5E ). However, we didn't observe colocalization of AIM2 and Rab7 in the macrophages co-cultured with apoptotic tumor cells induced by irradiation without antibodies ( Figure S5D ), indicating that AIM2 trafficking to phagosome following ADCP is mediated by FcgR pathway, but not merely by phagocytosis.
To further address how the recruited AIM2 senses tumor DNAs inside the phagosomes, we evaluated whether the phagosomal membrane was disrupted, as it was reported that rupture of the micronuclear membrane may lead to cGAS accumulation to sense the DNAs in the micronuclei (Mackenzie et al., 2017) . Indeed, we observed that annexin A2, which is involved in organelle-limiting membrane repair and stabilization, was recruited to the phagosomes of ADCP macrophages ( Figure 5F ), indicating that the phagosomal membrane was disrupted (F) The macrophages were cultured alone or co-cultured with BT-474 cells in the presence of trastuzumab. In addition, control IgG or an FcgR-neutralizing antibody cocktail was added to the co-culture. MFI (310 3 ) of Caspase-1 activation in macrophages were evaluated by flow cytometry. ### p < 0.001 versus untreated macrophages; *** p < 0.001 versus control ADCP-MF by Student's t tests. (G) Immunoblotting of cleaved and uncleaved caspase-1 and IL-1b in macrophages with trastuzumab-dependent BT-474 cell phagocytosis in which AIM2 were silenced by shRNAs. (H) Interactions of AIM2 with the adaptor protein ASC in indicated macrophages were determined by immunoprecipitation. (I) The tumor DNA was pre-labeled by 5-ethynyl-2 0 -deoxyuridine (EdU) in live BT-474 cells before induction of trastuzumab-mediated phagocytosis. Co-localization of tumor DNA and AIM2 in indicated macrophages was evaluated by confocal analysis. Scale bar, 5 mm. (J and K) Human macrophages were cultured alone or co-cultured with BT-474 cells (J) or mouse breast cancer E0771 cells with forced expression huErbB2 (K) in the presence of trastuzumab for 24 hr. The cytosolic DNA of macrophages was extracted and quantitated via qPCR using the primer specific for genomic (Polg1) or mitochondrial (Nd1) DNA. Copy numbers were normalized to the copy number of gDNA obtained from whole-cell extract. See also Figure S4 . Numerical values denote mean ± SEM (n = 5: [A] , [D] - [F] ; n = 3: [J] and [K] ). *** and ### p < 0.001 (versus untreated macrophages in A, J, and K or control ADCP-MF in D and E) by Student's t test.
after ADCP. Collectively, our data suggested that the DNA sensor, AIM2, is recruited to the phagosomes after ADCP via FcgR-SYK signaling and senses tumor DNAs in the phagosomes through disrupted phagosomal membranes.
Trastuzumab-Mediated PD-L1 and IDO Upregulation in TAMs Induces Immunosuppression In Vivo
Consistent with the ex vivo data, we observed that PD-L1 and IDO increased in the TAMs upon 4D5 treatment in vivo ( Figure 6A ). (legend continued on next page) Thus, we further explored whether ICIs can improve the response of tumor to therapeutic antibodies. Administration of anti-PD-L1 or/and IDO inhibitor only modestly inhibited human HER2 + tumor growth ( Figure 6B ). However, addition of either anti-PD-L1 or IDO inhibitor significantly improved the response of human HER2 + tumors to 4D5, and combined anti-PD-L1 and IDO inhibitor synergistically boosted up the therapeutic effects of 4D5 ( Figure 6B ).
To evaluate the effects of combined treatment with monoclonal antibodies and ICIs on the immune microenvironment, we examined the infiltration of NK and CD8 + T cells in the tumor grafts using immunohistochemistry. We observed that administration of 4D5, anti-PD-L1, or IDO inhibitor alone only slightly increased tumor-infiltrating NK and CD8 + T cells, while combined 4D5 with either anti-PD-L1 or IDO inhibitor tremendously increased the number of NK and CD8 + T cells in the tumors. More strikingly, in the animals receiving triple therapy of 4D5, anti-PD-L1 and IDO inhibitor, NK cells increased by $50-fold and CD8 + T cells increased by $30-fold ( Figures 6C and S6A) . Similarly, synergistic therapeutic effects of ICIs and trastuzumab were also observed in the humanized NOD/SCID/IL2rg null (NSG) mice bearing BT-474 xenografts ( Figures 6D-6F ). Together, these results suggested that combined application of ICIs improves the efficacy of therapeutic antibodies by enhancing anti-tumor immunity.
To investigate whether macrophage is indispensable for the benefits of the combined treatment, we inoculated mouse breast cancer E0771 cells with ectopic huErbB2 expression into the ErbB2 + ;Csf1 op/op mice. We observed that addition of anti-PD-L1 or/and IDO inhibitor did not enhance the therapeutic response of HER2 + tumors to 4D5 in the Csf1 op/op mice ( Figure 6G ), in which macrophages were ablated due to the loss of the major lineage regulator (Noy and Pollard, 2014) , and thus few TAMs were observed ( Figure 6A ). These data suggested that the improvement of anti-HER2 efficacy by ICIs is related to macrophage infiltration in tumor. Interestingly, tumors grew faster in the Csf1 op/op mice upon PD-L1 and IDO inhibition, suggesting that macrophages play a positive role in restraining tumor growth when immune checkpoints are blocked ( Figure S6B) .
To investigate the role of AIM2 and IL-1b in anti-HER2 treatment in vivo, we crossed the huErbB2 + mice with Aim2 À/À mice or treated the huERBB2 + mice with IL-1b-neutralizing antibody. We didn't observe any appreciable effect of Aim2 knockout or IL-1b blockade on tumor growth in the IgG group. Nevertheless, Aim2 knockout ( Figure 6H ) and IL-1b blockade ( Figure 6I ) significantly improved the efficacy of 4D5, suggesting that AIM2/IL-1b signaling reduces the anti-HER2 therapeutic efficacy in vivo.
To assess whether trastuzumab-induced immune remodeling in mouse models is similar in patients, we examined im-mune cell infiltration in the paired pre-treatment biopsies and post-treatment resected samples from patients who had received neoadjuvant trastuzumab-based therapy. It was reported that PD-L1 overexpression is mainly observed in the triple negative subtype of breast cancer compared to other subtypes, including HER2 + (Soliman et al., 2014) . Consistently, we observed only modest level of PD-L1 expression in both tumor cells and stromal cells in HER2 + breast tumor biopsies before neoadjuvant therapy. However, tumor-infiltrating macrophages, but not tumor cells ( Figure S7A ), expressed considerably higher levels of PD-L1 after trastuzumab-containing neoadjuvant therapy even PD-L1 was undetectable in the TAMs of pre-treatment biopsies (Figures 7A and 7C) . Similarly, the expression of IDO in macrophages, rather than tumor cells ( Figure S7A ), was also dramatically increased in the posttreatment samples compared to the paired pre-treatment biopsies in patients who had received trastuzumab-containing neoadjuvant therapy ( Figures 7A and 7C ). Nevertheless, HER2 + patients who had received neoadjuvant chemotherapy without trastuzumab did not exhibit enhanced PD-L1 or IDO expression in TAMs in the post-treatment samples ( Figures  7B and 7C) . Moreover, the number of PD-L1 + IDO + tumor-infiltrating macrophages was associated with poor response to trastuzumab-containing neoadjuvant therapy (Figure 7E , S7B, and S7C) and was negatively correlated with the infiltration of NK and CD8 + T cells ( Figures 7D and 7E) . Furthermore, we observed that PD-L1 and IDO levels were significantly increased after neoadjuvant trastuzumab therapy in the macrophages of the lymph nodes with tumor metastasis compared to those without metastasis ( Figure S7D ). In contrast, the difference in PD-L1 and IDO expression in the macrophages of metastatic or non-metastatic lymph nodes was not found in HER2 + patients treated with neoadjuvant treatment without trastuzumab ( Figure S7D ), suggesting that this was trastuzumab specific. Collectively, in vivo data from patients and mouse models suggest that PD-L1 and IDO expression is elevated in the TAMs following trastuzumab therapy and inhibits the anti-tumor function of NK and CD8 + T cells.
DISCUSSION
Macrophage phagocytosis leads to tumor elimination (Chao et al., 2010) , and inflammasome activation may induce adaptive immunity against tumors, as IL-1b and IL-18 cleaved by caspase-1 can directly enhance CD8 + T cells and NK cells activation (Ghiringhelli et al., 2009) . Surprisingly, our study showed that ADCP results in immunosuppressive macrophages with PD-L1 and IDO overexpression, which is mediated by inflammasome activation. Consistently, it has been reported that anti-CTLA-4 treatment increased (E) Human and mouse CD45 + cells were examined by flow cytometry to denote the infiltration of human immune cells in the xenografts of untreated NOD/SCID/ IL2rg null (NSG) mice or humanized mice receiving infusion of human hematopoietic stem cells (HSC). Representative flow plots in each group are shown. Numbers represent the percentages. (legend continued on next page) the expression of PD-L1 and VISTA in TAMs of prostate cancer patients . Both ADCC by innate immune cells and adaptive immunity (Park et al., 2010) play important roles in antibody-based therapy. Depletion of CD8 + and CD4 + T cells significantly diminishes the therapeutic effect of anti-HER2 antibody (Mortenson et al., 2013; Park et al., 2010) . The numbers of tumor-infiltrating lymphocytes determine the response to trastuzumab in large prospective clinical trials (Salgado et al., 2015) . We revealed that the compensatory immunosuppression caused PD-L1 and IDO in ADCP macrophages inhibits both ADCC by NK cells and immune response by T cells and thereby restrains or even overwhelms the anti-tumor effects of cancer cell phagocytosis and inflammasome activation brought by macrophages during antibody treatment. Indeed, we observed that that ADCP macrophages exerts anti-tumor effects in antibody treatment when both PD-L1 and IDO signaling are blocked. Collectively, our study advanced the understanding of the macrophage plasticity by uncovering a dual activity for ADCP in macrophages, eliminating tumor by engulfing cancer cells, while causing a concomitant undesired effect by upregulating immunosuppressive checkpoints.
PD-L1 expression is an important indicator of anti-PD-1/PD-L1 treatment for cancer patients. It has been shown that PD-L1 expression in tumor-infiltrating immune cells, particularly macrophages, is more closely associated with clinical responses to anti-PD-L1 treatment than PD-L1 expression in tumor cells (Zou et al., 2016) . Although PD-L1 and IDO are not abundantly expressed in HER2 + breast cancer before treatment, their overexpression can be induced in TAMs after neoadjuvant trastuzumab therapy. Our data suggest the necessity of monitoring immune checkpoint expression during antibody treatment and provide a rationale to use ICIs in various malignancies treated with therapeutic antibody, even in tumors whose immune checkpoint expressions are low at the treatment-naive state.
Pattern-recognition receptors can recognize pathogenic nucleic acids and initiate host antimicrobial responses. Recent studies have shown that cytosolic sensors in immune cells can also detect nucleic acids from tumor cells and trigger immune response (Corrales et al., 2017) . For example, tumor-derived DNA can activate the STING pathway in DCs, which induces type I IFN secretion and activates anti-tumor immunity (Woo et al., 2014) . Our study shows that another cytosolic DNA sensor, AIM2, detects tumor DNA in ADCP macrophages. Instead of activating anti-tumor immunity, AIM2 inflammasome activates IL-1b and upregulates PD-L1 and IDO in macrophages. Possible factors contribute to the distinct effects of cytosolic DNA sensors in macrophages and DCs are as follows: (1) Macrophages are the most abundant myeloid cells in tumors and most potent in phagocytosing tumor cells. In contrast, DCs constitute a very small proportion of tumor-infiltrating myeloid cells and are the only phagocytes carrying intact tumor antigen to lymph nodes and triggering immune response (Salmon et al., 2016) . (2) DCs, but not macrophages, can activate STING pathways by sensing tumor mtDNA and play a crucial role in the efficacy of CD47 blockade, which is FcgR independent (Xu et al., 2017) . (3) Macrophages express most activating and inhibitory FcgRs, while conventional DCs and plasmacytoid DCs mainly express inhibitory FcgRs and express low level of activating FcgRs (Guilliams et al., 2014) . Therefore, ADCP-induced activation of AIM2 inflammasome in macrophages seems to be a predominant pathway to suppress anti-tumor immunity, but the exact mechanisms by which tumor-derived DNA triggers different sensor pathways in different phagocytes warrant further studies.
Despite the phenomenon that tumor DNA activates cytosolic DNA sensors in phagocytes has been repeatedly reported (Woo et al., 2014; Xu et al., 2017) , the underlying mechanisms remain unknown. It has been reported that cGAS can shuttle to lysosome after activation (Gaidt et al., 2017) . In addition, the rupture of micronuclear membrane caused by genomic instability leads to cGAS accumulation to micronuclei, in which the self-DNA activates STING pathway (Mackenzie et al., 2017) . We observed AIM2, but not cGAS, traffic to phagosomes, whose membrane was disrupted in ADCP macrophages. The AIM2 recruitment to phagosomes in ADCP macrophages can be abrogated by FcgR-Syk inhibition. Moreover, our data showed that AIM2 activation inhibits the STING pathway in ADCP macrophages in tumors, which is in consistence with a recent report that inflammasome antagonizes STING pathway by caspase-1-mediated cGAS cleavage in viral infection (Wang et al., 2017) . Taken together, our data suggested FcgR signaling recruits AIM2 to phagosome and prioritizes AIM2 sensing DNA through disrupted phagosomal membrane. Subsequently, the activated caspase-1 inhibits STING activation by cleaving the cGAS.
In summary, we have identified an unexpected immunosuppressive effect of macrophages undergone ADCP by overexpressing PD-L1 and IDO. Moreover, our findings identify a specific mechanism of inflammasome activation by sensing DNA from phagocytosed tumor cells, which converts macrophages into an immunosuppressive phenotype. Our study provides the preclinical evidence and rationale for the synergistic effects and combinational use of ICIs and therapeutic antibody in cancer treatment.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Experimental Animals NOD/SCID/IL2r null (NSG) (Su et al., 2017) mice were purchased from the Jackson Laboratory and maintained as we previously described. B6;C3Fe a/a-Csf1 op/ /J (Csf1 op/ /J), C3FeLe.B6-a/a/J(C3Fe), B6.129P2-Aim2 Gt(CSG445)Byg /J (Aim2 KO) and B6.Cg-Pds5b Tg(Wap-ERBB2)229Wzw /J (B6 ErbB2 Tg) mice were purchased from the Jackson Laboratory and bred in the SPF animal facility of the Laboratory Animal Resource Center of Sun Yat-sen University in individually ventilated cages. B6 ErbB2 Tg mice were crossed with C3Fe to generate the human ErbB2 + mice with B6;C3 background. Csf1 op/ /J mice were crossed with human ErbB2 + mice to generate ErbB2 + ;Csf1 op/+ mice,which were then intercrossed to generate ErbB2 + Csf1 op/op mice. ErbB2 + ; Aim2 À/À mice were generated by crossing Aim2 KO mice and B6 ErbB2 Tg mice. Humanized mice were generated from NSG mice as we previously described (Su et al., 2017) . Briefly, 3-4 week female NSG mice were subjected to 2 cGy total body irradiation 12 hr before tail vein injection with 2 x10 5 hematopoietic stem cells isolated from fresh human cord blood by direct CD34 Cell Isolation Kit (Cat# 130-046-702, Miltenyi Biotec). Animal work was approved by the Institutional Review Boards and Animal Care and Use Committees of Sun Yat-Sen University.
Patients and Tissue Samples
Tumor samples were obtained from 307 invasive HER2 + breast carcinoma patients who were enrolled into the Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University (Guangzhou, China) from 2006 to 2017 with complete follow-up data and histopathologic slides. All cases were confirmed by pathological diagnosis and determined as HER2 + breast cancer (stage I-III) defined as 3+ staining by immunohistochemical analysis (Herceptest, Dako, Glostrup, Denmark) or HER2 amplification by fluorescent in situ hybridization (Pathvysion HER2 test, Abbott/Vysis, Des Plaines, IL, USA) in the pathology department of Sun Yat-sen Memorial hospital. All the patients received neoadjuvant therapy. Among them, 204 patients received Trastuzumab-containing neoadjuvant treatment and 103 patients received neoadjuvant chemotherapy without Trastuzumab. The neoadjuvant treatment regimens were as follows: doxorubicin 60mg/m 2 plus cyclophosphamide 600mg/m 2 every 3 weeks for four cycles, followed by paclitaxel (80mg/m 2 ) with or without Trastuzumab (initial loading dose of 4mg/kg/wk and subsequent doses of 2 mg/kg/w) administered weekly for 12 weeks; or Docetaxel 75mg/m 2 and cyclophosphamide 600mg/m 2 with or without Trastuzumab (initial loading dose of 8mg/kg and subsequent doses of 6 mg/kg) every 3 weeks for 4-6 cycles. There was no significant difference of the chemotherapy constitution and basic conditions between two groups with or without Trastuzumab. Therapeutic effects were evaluated according to the standard of RECIST (Response Evaluation Criteria in Solid Tumors). Complete Response (CR) was defined as disappearance of all lesions in both primary tumor and lymph nodes; Partial Response (PR) was defined as at least a 30% reduction in the sum of the longest diameter of target lesions; Progressive Disease (PD) was defined as at least a 20% increase in the sum of the longest diameter of target lesions; and Stable Disease (SD) was defined as neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD. CR and PR were classified as treatment sensitive, while SD and PD were classified as treatment resistant. Paired biopsy samples and surgical resected samples were collected from the same patient before and after neoadjuvant treatments. All samples were collected with informed consent from patients, and all related procedures were performed with the approval of the internal review and ethics boards of the Sun Yat-Sen Memorial Hospital.
Primary Human Immune Cells
Primary peripheral blood mononuclear cells were isolated from peripheral blood of healthy donors from the Guangzhou Blood Center. The blood samples were negative for antibodies against hepatitis C virus, hepatitis B virus, HIV, and syphilis. All related procedures were performed with the approval of the Internal Review and Ethics Boards of the Sun Yat-Sen Memorial Hospital.
METHOD DETAILS
Cell Culture and Treatment Human HER2 + breast cancer cell lines, BT-474 and SKBR3, human CD20 + Raji lymphoma cells were obtained from American Type Culture Collection and grown according to standard protocols. We knockout HER2 gene in BT-474 by CRISPR/Cas9 system as previously described. CRISPR/Cas9 HER2 plasmid was purchased from Addgene. The sequence of gRNA is CAGAGGCTGCG GATTGTGCG. Non-targeting gRNA was used as negative control. Lipofectamine 3000 (Cat# L3000015, Thermo Fisher) was used for transfection according to the manufacturer's instruction. The established BT474/HER2cells were cultured and selected in DMEM with 10% FCS and 2 mg/mL puromycin. The murine E0771 breast cancer line was purchased from CH3 Biosystems (New York, USA). In some experiments, E0771 cells were retrovirally transduced with the human HER2 antigen (ERB) as previously described (Kershaw et al., 2004) . Complementary strands were annealed and cloned into the Not I and EcoR I sites of pWSLV-07 vector. 5 3 10 5 cells were transduced with the viral vectors (multiplicity of infection[MOI] of 10) overnight at 37 C with 5 mg/ml polybrene (Sigma). The established human HER2 expressing cells were cultured and selected in DMEM with 10% FCS and 2 mg/mL puromycin. Peripheral blood monocytes were isolated by Ficoll density gradient centrifugation. Neutrophils were isolated by positive selection of CD66b + cells with microbeads (Cat# 130-104-913, Miltenyi Biotec). Macrophages were obtained by culturing monocytes in DMEM medium (GIBCO) supplemented with 10ng/ml M-CSF (Cat# 11792-HNAH, Sino Biological Inc.) and 10% FBS (GIBCO) for 6 days. In some experiments, macrophages were treated with 10 ng/ml IL-1b, IL-18, GM-CSF, IL-8, IL-6, CCL2, CCL8, CCL17, CCL18 or CXCL1 purchased from Peprotech (Cat# 200-01B, Cat# 200-18, Cat# 300-03-20, Cat# 200-08, Cat# 200-06, Cat# 300-04, Cat# 300-15, Cat# 300-30, Cat# 300-34 or Cat# 300-11). Monocyte-derived DCs (mo-DC) were generated by culturing monocytes with 5ng/ml IL-4 (Cat# 200-04-20, PeproTech) and 25ng/ml GM-CSF (Cat# 300-03-20, PeproTech) for 6 days. CD8 + T cells, naive CD4 + T cells and NK cells were isolated by magnetic-activated cell sorting using direct CD8 and CD56 Isolation Kit (Cat# 130-094-156 and 130-050-401, Miltenyi Biotec) naive CD4 + T Cells Isolation Kit II (Cat# 130-094-131, Miltenyi Biotec) according to the manufacturer's instructions. CD8 + T cells, CD4 + T cells, and NK cells were cultured in RPMI 1640 medium (GIBCO) supplemented with 25mmol/L HEPES, 4mmol/L L-glutamine, 25 mmol/L 2-mercaptoethanol, and 10% FBS at 37 C. Media were replaced every 2 days. The purity of cell populations was confirmed more than 90% by flow cytometry.
Tumor-specific CD8 + and CD4 + T cells were obtained as we previously described (Su et al., 2017) . Briefly, monocytes were cultured in DMEM supplemented with 25ng/ml GM-CSF (Cat# 300-03-20, PeproTech), 5ng/ml PeproTech) and 10% FBS for 5 days. Afterward, DCs were matured by incubated with 100ng/ml LPS and 500U/ml IFN-g (Cat# 300-02, PeproTech) for 48 hr and then pulsed with lysates (200 mg protein/1x10 6 cells/ml) of indicated tumor cells obtained by 5 freeze/ thaw cycles. After 24 hr, tumor-pulsed DCs were co-cultured with autologous CD8 + /CD4 + T cells (1:5) for 5 days.
ADCP Assay HER2 + breast cancer cells and Raji cells (1x10 5 ) pre-dyed by CellTtracker Deep Red Dye (Cat# C34565, Thermo Fisher) were co-cultured with macrophages pre-dyed by CellTracker CMFDA Dye (Cat# C7025, Thermo Fisher) with or without indicated concentration of Trastuzumab (Roche) and Rituximab (Roche), respectively. The ratio between tumor cells and macrophages was 1:5 and 3:1 for Trastuzumab and Rituximab respectively as previously described. After 24 hr, the cells were rigorously washed by PBS, digested by 10x TrypLE Selected Enzyme (Cat# A1217701, GIBCO) diluted 5x in PBS with 1mM EDTA and subjected for further experiments. To quantitate the tumor cells eradicated by ADCP, confocal analysis was performed. The percentages of tumor cell eradicated were calculated as 100-(100*(the number residual tumor cells co-culture with macrophages / the number tumor cells cultured alone)). In addition, to evaluate trogocytosis, purified unlabeled neutrophils and monocytes were incubated at 37 C 5% CO2 with CellTracker CM-DiL Dye (Cat# C7001, Thermo Fisher) labeled Raji cells at a 1:3 E:T ratio, in the presence or absence of 10 mg/ml Rituximab. Cells were then analyzed at 8 hr by flow cytometry. Gates to distinguish neutrophils/monocytes from Raji cells were established using side scatter or anti-CD14 (Cat# 367116, BioLegend) staining and DiL red fluorescence.
Generation of Macrophages/mo-DCs with ADCP
Human macrophages were co-cultured with HER2 + breast cancer cells (5:1) and Raji cells (1:3) with 1 mg/ml Trastuzumab and Rituximab respectively. In some experiments, Human macrophages were co-cultured with E0771 murine breast cancer cells with forced human ErbB2 expression (5:1) in the presence of 1 mg/ml Trastuzumab. Mo-DCs were co-cultured with BT-474 (5:1) with 1 mg/ml Trastuzumab to generate ADCP-DCs. In some experiments, 2 mg/ml latrunculina A (Cat# 10010630, Cayman), a neutralizing antibody cocktail (containing 5 mg/ml anti-human CD16 (Cat# 562162, BD), 5 mg/ml anti-human CD32a (Cat# AF1875, R&D) and 5 mg/ml anti-human CD64 (Cat# 555403, BD)), 5 mg/ml anti-human IL-1b antibody (Cat# GTX10749, GeneTex), 5 mg/ml, anti-human IFN-a antibody (Cat# 311301, Thermo Fisher), 5 mg/ml anti-human IFN-b antibody (Cat# 514003, Biolegend), 5 mg/ml anti-human IFN-g antibody (Cat# 506512, Biolegend), 5 mg/ml anti-human IL-10 neutralizing antibody (Cat# AF217, R&D), 100nM anti-human PGE2 neutralizing antibody (Cat# 10009814, Cayman), 5 mg/ml anti-human IL-12 p70 neutralizing antibody (Cat# MAB219, R&D), 5 mg/ml anti-human IL-23 p19 neutralizing antibody (Cat# AF1716, R&D), 10 mM Ac-YVAD-CMK (Cat# 100114, Cayman), 20 mM VX765 (Cat#S2228, Selleck), 5 mM R406 (Cat# HY-12067, MCE), or 40 mM Piceatannol (Cat# HY-13518, MCE) were added to the co-culture as indicated. Of note, IgG, served as controls in experiments above mentioned, may varied depending on the isotypes of the corresponding antibodies. The control for Trastuzumab/Rituximab is human IgG1 (SouthernBiotech, Cat# 0151K-01). The controls for FcgR neutralizing cocktails were mouse IgG1 isotype and normal goat IgG control (Cat# 554721, BD; Cat# AB-108-C, R&D). The isotype of anti-human IL-1b, anti-human IFN-a and anti-human IFN-g neutralizing antibody is mouse IgG1 (Cat# 554721, BD) . The isotype of anti-human IFN-a neutralizing antibody is normal rabbit IgG (Cat# 550875, BD). The isotypes of anti-human IL-10, anti-human PGE2, anti-human IL-12, and anti-human IL-23 neutralizing antibodies are mouse IgG1 isotype and normal goat IgG control (Cat# 554721, BD; Cat# AB-108-C, R&D). After 24 hr, the macrophages and mo-DCs were rigorously washed by PBS, digested by 10x TrypLE Selected Enzyme (Cat# A1217701, GIBCO) diluted 5x in PBS with 1mM EDTA. Macrophages were subsequently sorted by CD14 Isolation Kit (Cat# 130-050-201, Miltenyi Biotec) and mo-DCs were isolated by negative enrichment using EpCAM microbeads (Cat# 130-061-101, Miltenyi Biotec) according to manufacturer's instructions. In some experiments, macrophages were labeled with CMFDA before co-cultured and retrieved by fluorescence-activated cell soring after co-cultured. During the flow cytometry analysis, cells were first gated based on forward (FSC-A) and side (SSC-A) scatters to exclude debris and gated on DAPIor fixable viability dyeto exclude dead cells. More than 90% of isolated cell were positive for macrophage marker CD11b.
NK Cell Proliferation Assay
Autologous NK cells labeled with CTDR were cultured alone or co-cultured with macrophages with indicated treatments (2:1) in complete media (RPMI 1640 medium supplemented with 10% FBS) and stimulated with 100U/ml IL-2 and 50U/mL PeproTech) for 4 days. Afterward, the proliferation rate was evaluated by flow cytometry for Ki-67 staining (Cat# 350503, Biolegend) . In some experiments, 5 mg/ml anti-human PD-L1 neutralizing antibody (Cat# 329709, Biolegend), 5 mg/ml mouse IgG2b control (Cat# 400301, Biolegend) or 4 mg/ml 1-Methyl-D-tryptophan (1-MT, Cat# 452483, Sigma) was added in the co-culture.
T Cell Proliferation Assay
Autologous CD8 + T cells were labeled with 0.5 mM CFSE (Cat# C34554, Thermo Fisher) for 15 min at room temperature and incubated with aforementioned mature DCs (5:1) and indicated macrophages (2:1) labeled with CTDR in RPMI 1640 medium supplemented with 5 mg/mL IL-12, 25mmol/L HEPES, 4mmol/L L-glutamine, 25 mmol/L 2-mercaptoethanol, and 10% FBS. Proliferation of CD8 + T cells was measured by CFSE staining and flow cytometry after 4 days. In some experiments, 5 mg/ml anti-human PD-L1 neutralizing antibody, 5 mg/ml mouse IgG2b control (Cat# 400301, Biolegend) or 4 mg/ml 1-MT was added in the co-culture.
ADCC by NK Cells
Autologous NK cells labeled with CTDR were cultured alone or co-cultured with indicated macrophages (2:1) or mo-DCs (2:1) for 48 hr. In some experiments, 5 mg/ml anti-human PD-L1 neutralizing antibody, 5 mg/ml mouse IgG2b control (Cat# 400301, Biolegend) or 4 mg/ml 1-MT was added in the co-culture. Afterward, macrophages were depleted by CD14 Isolation Kit Miltenyi Biotec) . For mo-DCs-NK co-culture system, NK cells were retrieved by using CD56 microbeads Miltenyi Biotec) . NK cells were co-cultured with HER2 + breast cancer cells and Raji cells pre-stained with CMFDA (10:1) in the presence of 1 mg/ml Trastuzumab and Rituximab respectively for 8 hr. Afterward, cells were dyed with propidium iodide (Cat# 00-6990, eBioscience; 1:300) and analyzed by flow cytometry. Both CMFDA and propidium iodide positive cells were designated as killed tumor cells. CD107a (Cat# 328620, BioLegend), perforin (Cat# 308106, Biolegend) and granzymeB (Cat# 515403, Biolegend) of CMFDAor CTDR + NK cells were evaluated by surface or intracellular staining and flow cytometry.
Cytotoxicity of Tumor-specific CD8 + T Cells
Tumor-specific CD8 + T cells generated as described above were labeled with CTDR and cultured in the presence or absence of macrophages with indicated treatments (2:1) for 48 hr. In some experiments, 5 mg/ml anti-human PD-L1 neutralizing antibody, 5 mg/ml mouse IgG2b control (Cat# 400301, Biolegend) or 4 mg/ml 1-MT was added in the co-culture. Afterward, CD8 + T cells were collected by CD8 Isolation Kit (Cat# 130-094-156, Miltenyi Biotec) and mixed with target tumor cells pre-stained with CMFDA (10:1) for 18 hr. Afterward, cells were dyed with propidium iodide (Cat# 00-6990, eBioscience; 1:300) and analyzed by flow cytometry. Both CMFDA and propidium iodide positive cells were designated as killed tumor cells. Perforin (Cat# 308106, Biolegend) and granzymeB (Cat# 515403, Biolegend) CD8 + T cells were evaluated by intracellular staining and flow cytometry.
IFN-g Expression of Tumor-specific CD4 + T cells
Tumor-specific CD4 + T cells generated as described above were cultured in the presence or absence of macrophages with indicated treatments (2:1) for 48 hr. In some experiments, 5 mg/ml anti-human PD-L1 neutralizing antibody, 5mg/ml mouse IgG2b control (Cat# 400301, Biolegend) or 4 mg/ml 1-MT was added in the co-culture. Afterward, CD4 + T cells were collected by CD4 microbeads (Cat# 130-045-101, Miltenyi Biotec) and mixed with BT-474 cells in the presence or absent of Trastuzumab for 24 hr. Afterward, cells were stained with anti-CD4 (Cat# 317428, Biolegend) and anti-IFN-g (Cat# 554700, BD) and analyzed by flow cytometry.
Induction of Apoptosis
Primary macrophages were incubated in serum-starved medium (0%FBS) for 24 hr to generate apoptotic macrophages. BT-474 cells were irradiated, at 37 C, with 20Gy in RS 2000 X-ray biological irradiator (Rad Source., USA), or cultured in complete medium in the presence of Trastuzumab to generate apoptotic tumor cells.
Microarray
Total RNA was extracted from macrophages with indicated treatments (5x10 6 cells) using the TRIzol Reagent (Cat# A33251, Thermo Fisher) following the manufacturer's instructions. The quality of extracted RNA was assessed using the NanoDrop ND-2000 spectrophotometer. mRNA expression was analyzed by Agilent Array platform (Technologies Inc., USA) from NCBI's Gene Omnibus Express (GEO) repository (accession numbers 119342). qPCR of Cytosolic DNA Cytosolic DNA was extracted as previously described (Xu et al., 2017) . 1 3 10 6 of purified ADCP-macrophages were divided into two equal aliquots, and one aliquot was lysed in 100 mL of 50 mM NaOH and boiled for 15 min. These whole cell lysates were neutralized with 10 mL of 1 M Tris-HCl pH 8 (10x), which served as normalization controls for total DNA. The other equal aliquots were resuspended in 100 mL cytosolic extract buffer containing 150 mM NaCl, 50 mM HEPES and 25 mg/ml digitonin (Cat# 300410, Sigma) and incubated for 10 min on ice for plasma membrane permeabilization. Then cells were centrifuged to pellet intact cells. The cytosolic supernatants were collected and centrifuged at maximal speed for 10 min to pellet the remaining cellular debris. DNA from whole cell lysates or cytosolic extract was subjected to protease K for 1 hr and purified using DNA Clean & Concentrator (Cat# D4003, ZYMO RESEARCH). Quantitative PCR was performed on both whole-cell extracts and cytosolic fractions using gDNA primers(human or mouse) and mtDNA primers(human or mouse). gDNA/mtDNA CT values obtained from the cytosolic fractions were normalized to gDNA abundance for whole-cell extracts to control the variations in cell number among samples.
Flow cytometry
qRT-PCR
Total RNA was extracted from macrophages with indicated treatments and quantitative reverse transcription PCR (qRT-PCR) was performed using SYBR Premix Ex Taq kit (TaKaRa, Japan) according to the manufacturer's instruction. Data were collected and analyzed with a LightCycler 480 instrument (Roche). The primer sequences are listed in Table S1 .
ELISA IL-1b ELISA kits were purchased from eBioscience (Cat# 887261) and IFN-a, IFN-b and IFN-g ELISA kit were all from MultiSciences, (Cat# 70-EK1992, 70-EK1236-96, 70-EK1802 respectively). All experiments were performed according to the manufacturer's instructions.
Western Blot
For protein extraction, macrophages were homogenized by Ripa (Millipore) with proteinase inhibitor cocktail (Cat# 78446, Thermo Fisher). The Protein Recovery Kit (Cat# P1255, Applygen Technologies Inc) was used to increase the concentration of the protein up to 200 times referring to the manufacturer's instructions. Total protein was quantified using the Pierce BCA Protein Assay Kit (Cat# 23225, Thermo Fisher). Equal amounts of the lysates were fractionated by 12% SDS-PAGE and electrotransferred to nitrocellulose membranes (Whatman Protran nitrocellulose membrane; neoLab). After blocking with with TBS/0.05% Tween-20/5% skim milk, the membranes were probed with antibodies against IL-1b (Cat# 12703, Cell Signaling Technology; 1:1000), caspase-1 (Cat# 3866, Cell Signaling Technology; 1:1000), AIM2 (Cat# 12948, Cell Signaling Technology; 1:1000), ASC (Cat# 13833, Cell Signaling Technology; 1:1000), IPAF (Cat# 12421, Cell Signaling Technology; 1:1000), NLRP1 (Cat# 4990, Cell Signaling Technology; 1:1000), NLRP3 (Cat# 13158, Cell Signaling Technology; 1:1000), TLR9 (Cat# 13674, Cell Signaling Technology; 1:1000), STING (Cat# 13647, Cell Signaling Technology; 1:1000), pIRF3 (Cat# 29047, Cell Signaling Technology; 1:1000), pTBK1 (Cat# 5483, Cell Signaling Technology; 1:1000), cGAS (Cat# 15102, Cell Signaling Technology; 1:1000), tubulin (Cat# HRP-66031, Proteintech; 1:10000), GAPDH (Cat# HRP-60004, Proteintech; 1:10000). Peroxidase-conjugated anti-rabbit antibody (Cat# 7974 Cell Signaling Technology; 1:3000) were used as secondary antibody and signals were enhanced by chemiluminescence (ECL; Thermo Fisher).
Co-immunoprecipitation
Macrophages were lysed by incubation for 15 min at 4 C with NP 40 lysis buffer (Cat# 87787, Thermo Fisher) with proteinase inhibitor cocktail (Cat# 78446, Thermo Fisher). After a centrifugation at 14000 g for 15min at 4 C, the supernatant was prepared to perform immunoprecipitation and incubated with Dynabeads Protein A (Cat# 10001D, Thermo Fisher) and rabbit anti-human ASC antibody (Cat# 13833, abcam; 1:50) or rabbit anti-human Rab7 antibody (Cat# 9367, Cell Signaling Technology; 1:100) for 1 hr at room temperature. Dynabeads-antigen-antibody complex was collected after a centrifugation at 14000rpm for 5 s and washed by PIPA buffer three times. The complex was resuspended with 60 ul 2x simple buffer and cooked for 5 min, followed by analyzing the supernatant by SDS-PAGE and immunoblotting.
ShRNA Mediated Silencing
Lentivirus packaging was made by GenePharma Inc (Shanghai, China). A lentiviral vector plasmid pGag/Pol was used in our study to construct the stable clones. Lentiviral shRNAs targeting AIM2, NLRP1, NLRP3, IPAF, STING, TLR9, p65, STAT1, TBK1 and AMPK were obtained from Genepharma and shRNA Silencing sequences are listed in Table S2 . The control shRNA (5'-TTCTCCGAACGTGTCACGT-3') was confirmed have no impact on NLRP1, NLRP3, IRP3, STING, TLR9, p65, STAT1, TBK1 and AIM2 expression. Primary human macrophages were transduced with the lentiviral vectors. Briefly, 1x10 6 cells were transduced with the lentiviral vectors (multiplicity of infection[MOI] of 10) overnight at 37 C with 5 mg/ml polybrene (Sigma).
Animal Experiments
We injected 5 3 10 5 E0771 cells with human HER2 stable expression (E0771/ ErbB2 + ) into the fat pad of human HER2 + mice (ErbB2 + mice, ErbB2 + ;Csf1 op/op mice, or ErbB2 + ;Aim2 À/À mice) and 1 3 10 7 BT-474 cells into humanized mice respectively. When the tumors were palpable, 8 mice per group were randomized for different treatments.
Murine anti-human HER2 antibody 4D5 kindly provided by Dr. Mandana Asgharnejad (Genentech, South San Francisco, California; MTA ID: OR-214993) and Trastuzumab (Roche) was intravenously injected at a loading dose of 4 mg/g, followed by weekly injections of 2 mg/g into HER2 + mice and humanized mice respectively, mimicking human dosing regimens as previously described (Clynes et al., 2000) . In some experiments, mice were treated with 100mg/mouse monoclonal anti-mouse or anti-human PD-L1 antibody (Cat# BE0101 or BE0285, BioXcell) intraperitoneally every 3 days or/and 10mg/mouse 1-MT (Cat# 452483, Sigma) intraperitoneally every day as previously described (Aloulou et al., 2016; Hou et al., 2009) . In some experiment, ErbB2 Tg mice were treated with 50 mg twice weekly anti-IL-1b (Cat# BE0246, BioXCell) in the presence of 4D5 or IgG. Control mice received equal amounts of isotope control antibodies (Cat# BE0091, BioXcell), along with 4D5 or IgG, as previously described (Coffelt et al., 2015) . The control for 4D5 is mouse IgG1 which was kindly provided by Genetech company. The control for Trastuzumab is human IgG1 (Cat# 0151K-01, South-ernBiotech). The control of anti-mouse IL-1b neutralizing antibody is Armenian Hamster IgG (Cat# BE0091, BioXcell), the control of anti-mouse PD-L1 neutralizing antibody is rat IgG2 (Cat# BE0090, BioXcell).
The tumor volumes calculated by the formula: volume = width 2 x length/2 were recorded every 3 days. Mononuclear cells in tumor xenografts were isolated. Briefly, tumor xenografts were minced into small (1 to 2 mm) pieces and digested with 0.125% trypsin for 30-40 min at 37 C under constant shaking. The cells were sequentially filtered through 500 mm mesh, 100 mm, and 70 mm cell strainer. The cells were then centrifuged at 2500rpm for 15 minutes with 1ml cell suspension above 5 mL 45% Percoll in the middle and 5ml 60% Percoll at the bottom in a 15 mL tube. Mononuclear cells were collected from the cell layer in the interphase between 45% and 60% Percoll. All isolated mononuclear cells were analyzed for human reconstitution by flow cytometry. All procedures were approved by the Institutional Review Boards and Animal Care and Use Committees of Sun Yat-Sen University. 5-Ethynyl-2 0 -deoxyuridine (EdU) (Cat# BCK-FC555-50, Sigma) for 3 days to label tumor DNA. Afterward, the cells were rigorously washed by PBS and subjected to the ADCP assay as described above. The cells were counterstained with Hoechst 33342 (Ca# H21492, Thermo Fisher) and imaged using a confocal laser-scanning microscope (Carl Zeiss) with a core data acquisition system (Applied Precision).
QUANTIFICATION AND STATISTICAL ANALYSIS
The information about statistical details and methods is indicated in the figure legends, text or methods. The measurements of all statistical values were performed using Graphpad Prism 7.0, unless otherwise described in the figure legends or methods. Error bars in the experiments indicate standard error of the mean (SEM) or standard deviation (SD) for a minimum of three independent experiments.
DATA AND SOFTWARE AVAILABILITY
The microarray data are available at the public databases. The accession numer for the microarray data reported in this paper is GEO: The macrophages were cultured alone or co-cultured with BT-474 cells in the presence of Trastuzumab. In addition, control IgG or a FcgR neutralizing antibody cocktail was applied to the co-culture. PD-L1 and IDO levels in macrophages were evaluated by flow cytometry. Mean ± s.e.m. x 10 3 of MFI. n = 5; ***p < 0.001 compared with untreated MF (the 1 st group); ### , p < 0.001 compared with control ADCP-MF (the 2 nd group) by Student's t tests. (C) Human macrophages were cultured alone (MF), or co-cultured with Raji cells in the absence (TC-MF) or presence of Rituximab (ADCP-MF) for 24 hr. Their PD-L1 and IDO levels were evaluated by flow cytometry. Mean ± s.e.m. x10 3 of mean fluorescence intensity (MFI). n = 5; ***p < 0.001 compared with macrophages cultured alone by Student's t tests.
(legend continued on next page) 
